Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SHP099

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

PTPN11 inhibitor

Related drugs:

KRAS mutation	Solid Tumor	KRAS mutation	Solid Tumor	SHP099 Sensitive: D – Preclinical SHP099 Sensitive : D	SHP099 Sensitive: D – Preclinical SHP099 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D
KMT2D mutation	Lung Cancer	KMT2D mutation	Lung Cancer	afatinib + SHP099 Sensitive: D – Preclinical afatinib + SHP099 Sensitive : D	afatinib + SHP099 Sensitive: D – Preclinical afatinib + SHP099 Sensitive : D
ALK positive	Lung Cancer	ALK positive	Lung Cancer	alectinib + SHP099 Sensitive: D – Preclinical alectinib + SHP099 Sensitive : D	alectinib + SHP099 Sensitive: D – Preclinical alectinib + SHP099 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + SHP099 Sensitive: D – Preclinical gilteritinib + SHP099 Sensitive : D	gilteritinib + SHP099 Sensitive: D – Preclinical gilteritinib + SHP099 Sensitive : D